Cost-minimization Analysis of 3 Therapeutic Regimes of Edaravone Combined Use in the Treatment of Acute Cerebral Infarction
10.6039/j.issn.1001-0408.2016.05.02
- VernacularTitle:3种依达拉奉联合用药方案治疗急性脑梗死的最小成本分析
- Author:
Yuan QIAO
;
Qiuping CHU
- Publication Type:Journal Article
- Keywords:
Acute cerebral infarction;
Edaravone;
Ginkgo dipyidamolum;
Argatroban;
Sodium ozagerl;
Drug combination;
Cost-minimization analysis
- From:
China Pharmacy
2016;27(5):581-583
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the pharmacoeconomic effect of Ginkgo dipyidamolum,argatroban or sodium ozagerl combined with edaravone in the treatment of acute cerebral infarction(ACI). METHODS:In retrospective study,64 ACI patients were divided into group A(Ginkgo dipyidamolum+edaravone,22 cases),group B(argatroban+edaravone,19 cases)and group C (sodium ozagerl+edaravone,23 cases). Therapeutic efficacies were observed after 7-14 days of treatment;therapy cost was calculat-ed,and cost-minimization analysis was used to evaluate pharmacoeconomics. RESULTS:There was no statistical significance in to-tal effective rate among 3 groups(P>0.05);the costs of group A,group B and group C were 8 746.36 yuan,10 770.64 yuan and 8 264.67 yuan. Results of sensitivity analysis were in line with those of cost-minimization analysis. CONCLUSIONS:Therapy plan of sodium ozagerl+edaravone is the economical regime in the treatment of ACI .
